CLDN6 (Claudin 6)

This study highlights the role of CLDN6 in cell adhesion, migration, and proliferation of GCT cells, suggesting that, in addition to its suitability as a therapeutic target, CLDN6 may also play a putative role during tumor progression.

The LNP-sa-mRNA formulation was stable and uniform, enabling robust CLDN6-Nb-BiTE expression, antigen-dependent cytotoxicity, and cytokine release in vitro, while sustained CLDN6-Nb-BiTE production in vivo promoted T-cell recruitment and durable tumor control without systemic toxicity. Overall, our work introduces the first CLDN6-Nb-BiTE delivered by sa-mRNA, establishing a foundation for next-generation ovarian cancer immunotherapy.

P1, N=282, Recruiting, Xencor, Inc. | N=212 --> 282

CLDN6-targeted therapies may not be effective for teratoma. In contrast, i12p was prevalent across all stages of GCT progression, suggesting its potential as a biomarker for identifying viable GCT.

GTN exhibits frequent expression of several established ADC targets, particularly Nectin4 and FOLR1. These findings provide a molecular rationale for biomarker-driven investigation of ADC-based therapeutic strategies in refractory or recurrent GTN.

These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.

P1, N=22, Completed, Chugai Pharmaceutical | Active, not recruiting --> Completed | N=231 --> 22 | Trial completion date: Oct 2029 --> Jan 2026 | Trial primary completion date: Oct 2029 --> Jan 2026

ARC101 also demonstrated a favorable pharmacokinetic profile in cynomolgus monkeys, low immunostimulatory responses in ex vivo human donor assays, and robust biophysical properties compatible with standard antibody manufacturing. Collectively, these findings support the clinical advancement of ARC101 as a differentiated, CLDN6-specific bispecific immunotherapy with exceptional tumor selectivity and optimized T cell activity for the treatment of solid tumors.

Management of patients with GCT requires a multidisciplinary approach and patients with advanced disease being considered for surgery or those with refractory disease should be referred to a high-volume treatment center. Outcomes in refractory GCT remain poor, but several novel treatment options and approaches are being explored in clinical trials to improve cure rates in this patient population.

P1, N=100, Recruiting, Primelink BioTherapeitics(ShenZhen) Limited | Not yet recruiting --> Recruiting

And the 11.1 MBq [¹⁷⁷Lu]Lu-DOTA- IMAB027 group significantly inhibited tumor growth, prolonged survival, and showed lower toxicity than non-radioactive drug treatment groups. ⁸⁹Zr/¹⁷⁷Lu-labeled IMAB027 holding promise as a potentially viable therapeutic approach for clinical management of gynecological cancers.

This review focuses on future progress in TNBC therapy that relies on integrating precision antigen targeting, immune cell engineering, and advanced delivery technologies. Together, mRNA-based immunotherapies hold immense promise to overcome current therapeutic barriers and pave the way for more effective, personalized treatment strategies in TNBC.